Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Former Takeda CEO Yasuchika Hasegawa Dies at 80
Yasuchika Hasegawa, the former president and CEO of Takeda Pharmaceutical who helped transform the Japanese drug maker into a global pharmaceutical player, died on July 3 at the age of 80, the company said on September 11. Hasegawa joined Takeda…
To read the full story
Related Article
- Takeda Advisor Hasegawa, Herald of Takeda Globalization, Steps Down
July 1, 2019
- Takeda Chairman Hasegawa Officially Steps Aside as Adviser
June 29, 2017
- Takeda Chairman Hasegawa to Retire, Become Adviser in June
April 14, 2017
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
BUSINESS
- Sanofi Japan Bets on Beyfortus Track Record with NIP Inclusion in Sight
November 11, 2026
- Vital KSK’s Medleap Pivots to In-House Drug Filings, Eyes 2029 Launch
November 10, 2026
- Alfresa, Partners Seal Share Deal to Formalize Biosimilar JV
November 10, 2026
- Japan Ethical Drug Sales Rise 3.5% in September: Crecon
November 10, 2026
- Shionogi Grabs Japan Nod for Updated COVID Vaccine
November 10, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…